Edition:
India

Ascendis Pharma A/S (ASND.OQ)

ASND.OQ on NASDAQ Stock Exchange Global Select Market

109.49USD
20 Sep 2019
Change (% chg)

$1.80 (+1.67%)
Prev Close
$107.69
Open
$107.85
Day's High
$109.69
Day's Low
$106.84
Volume
87,814
Avg. Vol
71,042
52-wk High
$133.61
52-wk Low
$53.29

Latest Key Developments (Source: Significant Developments)

Ascendis Pharma A/S Reports Q1 Loss Per Share Of EUR 1.24
Friday, 31 May 2019 

May 30 (Reuters) - Ascendis Pharma A/S ::REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE EUR 1.24.Q1 REVENUE EUR 5.4 MILLION.Q1 REVENUE ESTIMATE EUR 370,000 -- REFINITIV IBES DATA.Q1 EARNINGS PER SHARE ESTIMATE EUR -1.00 -- REFINITIV IBES DATA.AS OF MARCH 31, 2019, COMPANY HAD CASH AND CASH EQUIVALENTS OF EUR 696.7 MILLION COMPARED TO EUR 277.9 MILLION AS OF DECEMBER 31, 2018.  Full Article

Ascendis Pharma A/S Reports Full Year 2018 Financial Results
Thursday, 4 Apr 2019 

Ascendis Pharma A/S ::ASCENDIS PHARMA A/S REPORTS FULL YEAR 2018 FINANCIAL RESULTS.ASCENDIS PHARMA A/S - AS OF DEC 31, 2018, HAD CASH AND CASH EQUIVALENTS OF EUR 277.9 MILLION VERSUS EUR 195.4 MILLION IN PRIOR YEAR PERIOD.  Full Article

Ascendis Pharma Says Once-Weekly Transcon Growth Hormone Demonstrated Superiority On Primary Endpoint
Monday, 4 Mar 2019 

March 4 (Reuters) - Ascendis Pharma A/S ::ASCENDIS PHARMA ANNOUNCES ONCE-WEEKLY TRANSCON™ GROWTH HORMONE DEMONSTRATED SUPERIORITY ON PRIMARY ENDPOINT COMPARED TO A DAILY GROWTH HORMONE IN PHASE 3 HEIGHT TRIAL FOR PEDIATRIC GROWTH HORMONE DEFICIENCY.ASCENDIS PHARMA A/S - RESULTS FROM TRIAL INDICATE THAT TRANSCON HGH WAS GENERALLY SAFE AND WELL-TOLERATED.ASCENDIS PHARMA A/S - ASCENDIS PLANS A CLINICAL DATABASE LOCK FOR TRANSCON HGH PHASE 3 PROGRAM IN Q3 OF 2019.ASCENDIS PHARMA - TO SUBMIT BIOLOGICS LICENSE APPLICATION (BLA) WITH FDA FOR TRANSCON HGH TO TREAT PEDIATRIC GHD IN FIRST HALF OF 2020.  Full Article

Ascendis Pharma Expects Results From Phase 3 Trial Of Transcon HGH In Q1
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Ascendis Pharma A/S ::ASCENDIS PHARMA A/S - TOP-LINE RESULTS FROM PHASE 3 HEIGHT TRIAL FOR TRANSCON HGH ARE EXPECTED IN Q1.ASCENDIS PHARMA A/S - TOP-LINE RESULTS FROM FLIGHT TRIAL (SWITCH) ARE EXPECTED IN Q2.ASCENDIS PHARMA A/S - TOP-LINE RESULTS FROM A PHASE 2 TRIAL FOR TRANSCON PTH ARE EXPECTED IN Q4.ASCENDIS PHARMA A/S - A PHASE 2 TRIAL OF TRANSCON CNP IN CHILDREN WITH ACHONDROPLASIA IS EXPECTED TO BE INITIATED IN Q3.ASCENDIS PHARMA A/S - HAS ESTABLISHED ONCOLOGY AS ITS SECOND INDEPENDENT THERAPEUTIC AREA.  Full Article

Ascendis Pharma Reports Third Quarter 2018 Financial Results
Thursday, 29 Nov 2018 

Nov 28 (Reuters) - Ascendis Pharma A/S ::REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE EUR 0.81.Q3 EARNINGS PER SHARE ESTIMATE EUR -1.06 -- REFINITIV IBES DATA.ON TRACK TO REPORT TOP-LINE RESULTS IN Q1 OF 2019 FOR PHASE 3 HEIGHT TRIAL.  Full Article

Ascendis Pharma Announces Positive Preliminary Phase 1 Data For Transcon CNP
Thursday, 29 Nov 2018 

Nov 28 (Reuters) - Ascendis Pharma A/S ::ASCENDIS PHARMA A/S ANNOUNCES POSITIVE PRELIMINARY PHASE 1 DATA FOR TRANSCON CNP.ASCENDIS PHARMA A/S - COMPANY PLANS TO INITIATE A PHASE 2 PROGRAM OF TRANSCON CNP IN PEDIATRIC SUBJECTS WITH ACHONDROPLASIA IN MID-2019.ASCENDIS PHARMA A/S - TRANSCON CNP PHASE 1 RESULTS REINFORCE PRECLINICAL DATA AND SUPPORT TARGET PRODUCT PROFILE.ASCENDIS PHARMA A/S - TRANSCON CNP DELIVERED CONTINUOUS EXPOSURE OF CNP AT TARGET LEVELS FOR SEVEN DAYS WITH A SINGLE SUBCUTANEOUS ADMINISTRATION.  Full Article

Ascendis Pharma Q2 Loss Per Share EUR 0.55
Thursday, 30 Aug 2018 

Aug 29 (Reuters) - Ascendis Pharma A/S ::REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE EUR 0.55.Q2 EARNINGS PER SHARE VIEW EUR -0.90 -- THOMSON REUTERS I/B/E/S.  Full Article

Ascendis Pharma Files For Potential Mixed Shelf Offering, Size Not Disclosed - SEC Filing
Thursday, 31 May 2018 

May 30 (Reuters) - Ascendis Pharma A/S ::ASCENDIS PHARMA A/S FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING.  Full Article

Ascendis Pharma Initiates Submissions In Australia To Enter Study With Transcon CNP
Thursday, 21 Dec 2017 

Dec 20 (Reuters) - Ascendis Pharma A/S ::ASCENDIS PHARMA SAYS ON DEC 20, INITIATED REGULATORY SUBMISSIONS IN AUSTRALIA TO ENTER INTO FIRST HUMAN CLINICAL STUDY WITH TRANSCON CNP - SEC FILING.  Full Article

Ascendis Pharma A/S Q3 loss per share EUR 1.04
Friday, 17 Nov 2017 

Nov 16 (Reuters) - Ascendis Pharma A/S ::Ascendis Pharma A/S reports third quarter 2017 financial results.Q3 loss per share EUR 1.04.Q3 earnings per share view EUR -0.74 -- Thomson Reuters I/B/E/S.  Full Article